Acclaimed Life Sciences Leaders Launch Impact Investment Firm to Accelerate Health Equity

Impact investment firm focuses on investing in therapies for diseases that disproportionately affect underserved populations, including ethnic minorities and the LGBTQ+ community

NEW YORK--(BUSINESS WIRE)--Syridex Bio ("Syridex" or "the Firm"), an impact-driven, life sciences-focused firm investing in therapies that address the needs of underserved communities, has officially launched. The firm’s founding, by a team of established experts with decades of experience at the nexus of life sciences, entrepreneurship, and investing, reflects the urgent need for investment intentionally directed toward addressing health inequities and the largely untapped potential for robust financial returns in this often-overlooked space.

Launching in the context of the global coronavirus pandemic and the vast healthcare inequities it revealed, Syridex Bio’s investment focus is on funding therapies for diseases that disproportionately affect underserved populations, including ethnic minorities, the LGBTQ+ community, and rural dwellers. The firm’s investment targets include in-development drugs and medical therapies that tackle the world’s greatest health outcome disparities. By leveraging venture creation and private equity strategies, Syridex aims to finance the development of medical solutions that improve health outcomes and reduce disparities in underserved communities and thereby advance health equity in both absolute and relative terms.

Squire Servance, Founder and Managing Partner, has spent more than a decade working in the biotechnology, pharmaceutical, and life sciences industries. Prior to founding Syridex, he served as Senior Vice President, General Counsel & Corporate Secretary at Repligen Corporation, a bioprocessing-focused life sciences company, where he led the legal, corporate secretary, compliance, and enterprise risk functions. He also counseled the company’s Board of Directors and senior management. Servance joined Repligen from Baxter International, Inc. where he led the global legal team supporting its multi-billion-dollar global pharmaceuticals business.

“Syridex Bio is founded on the fundamental belief that everyone deserves the opportunity to live a healthy life,” said Servance. “Accelerating progress toward health equity requires unified action by a range of leaders and stakeholders, and it is increasingly clear that the investor community must play a central role. Driven by our focus on positive impact, we leverage a market-based approach to invest in therapies that intentionally serve the underserved – thus, laying the foundation for true equality in healthcare and opening the door to a brighter, healthier global future.”

The minority-led firm, guided by a world-class advisory board, draws on deep relationships across the global pharmaceutical and biotechnology industries to source investment opportunities in innovative, best-in-class clinical stage or near-clinical stage therapies.

The advisory board is led by:

• Kamil Ali-Jackson, a serial entrepreneur, executive, board member, and legal counsel for emerging, mid-size, and large life sciences companies, who has also co-founded several specialty pharmaceutical and biopharmaceutical companies
• Owen May, Founder and CEO of May Davis Partners, an investment bank and advisory practice, who brings vast experience in corporate finance, IPOs, and business development
• Anindya Roychowdhury, former Partner and Head of Deal Advisory at KPMG, who is a demonstrated leader in starting profit centers and growing them into market leaders, with extensive startup and early-stage company experience
• Veleka Peeples-Dyer, an accomplished life sciences executive, who has a long track record of advising pharmaceutical, biotechnology, medical device, and other companies on FDA regulatory, legal, and global compliance matters, as a strategic business and legal advisor

“Syridex Bio’s investment strategies intend to offer investors market-based pathways to address the most acute disparities across the healthcare system,” said advisory board member Kamil Ali-Jackson. “Investors who channel capital into such potentially transformative therapies will gain access to a compelling opportunity with competitive returns, while also actively driving social justice in healthcare.”

About Syridex Bio:
Syridex Bio is an impact-driven, life sciences-focused venture creation and private equity firm investing in therapies that address the needs of underserved communities. The firm draws on deep relationships across the global pharmaceutical and biotech industries to source innovative, best-in-class clinical stage or near-clinical stage therapies. Then, it invests in development to bring to market novel drugs and treatments that might otherwise go undeveloped. Syridex Bio focuses on two primary investment strategies: venture creation, which builds sustainable companies around innovative products the firm acquires from life sciences companies and institutions; and private equity, which privatizes and creates value in undervalued public pharmaceutical and biotechnology companies.

For more information, please visit www.syridexbio.com.

Media:
Sarah Churbuck
BackBay Communications
syridex.bio@backbaycommunications.com